Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Knut Eis

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor ModelsUlrich Lücking, Lars Wortmann, Antje M Wengner, et al.
Journal of Medicinal Chemistry|December 20, 2018
Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5Duy Nguyen, Clara Lemos, Lars Wortmann, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonistsDouglas L Orsi, Steven J Ferrara, Stephan Siegel, et al.
Chemmedchem|September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.
Cancer Discovery|October 15, 2025
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung CancerFranziska Siegel, Stephan Siegel, Kristýna Kotýnková, et al.
Cell Chemical Biology|March 27, 2024
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signalingKeith Graham, Philip Lienau, Benjamin Bader, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor ModelsUlrich Lücking, Lars Wortmann, Antje M Wengner, et al.
Journal of Medicinal Chemistry|December 20, 2018
Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5Duy Nguyen, Clara Lemos, Lars Wortmann, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonistsDouglas L Orsi, Steven J Ferrara, Stephan Siegel, et al.
Chemmedchem|September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.
Cancer Discovery|October 15, 2025
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung CancerFranziska Siegel, Stephan Siegel, Kristýna Kotýnková, et al.
Cell Chemical Biology|March 27, 2024
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signalingKeith Graham, Philip Lienau, Benjamin Bader, et al.
Pageof 2